Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xilio Therapeutics, Inc. (XLO)
USD9.00
-0.03 (-0.33%)
US NASDAQ Healthcare Biotechnology
Address
828 Winter Street 2451
Waltham, MA, US
Waltham, MA, US
CEO
Rene Russo
Website
xiliotx.com
IPO
2021-10-22
CIK 1840233 ISIN US98422T2096
Description
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.00
-0.03 (-0.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
43.7K
Beta
-0.12
Float Shares
2.14M
Free Float %
35.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.70% | +0.59% | +6.82% | +14.32% | -20.26% | -5.58% | -13.67% | -80.19% | -96.22% | -96.22% | -96.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
9.00
Low
98.00
+988.9%
Consensus
98.00
+988.9%
Median
98.00
+988.9%
High
98.00
+988.9%
DCF (Unlevered)
36.25
+302.8%
DCF (Levered)
18.78
+108.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
98.00
+988.9%
|
Quality scores
Altman Z-Score
-3.04
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+589.9% ★ Q1'26: +331.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+72.5% ★ Q1'26: +77.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-36.2% Q1'26: -181.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-95.9% Q1'26: -111.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +79.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,087.0% Q1'26: +2,963.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.17× Q1'26: -0.12× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 2.36M (-100.0%)
|
6.34M
est: 7.70M (-17.6%)
|
43.77M
est: 41.00M (+6.7%)
|
36.01M
36.01M – 36.01M
-12.2% YoY
|
28.55M
28.55M – 28.55M
-20.7% YoY
|
7.43M
7.43M – 7.43M
-74.0% YoY
|
4.15M
4.15M – 4.15M
-44.1% YoY
|
2.34M
2.34M – 2.34M
-43.6% YoY
|
| EBITDA |
-77.23M
est: 507.2K (-15,326.9%)
|
-58.00M
est: 1.66M (-3,599.9%)
|
-40.44M
est: 8.82M (-558.4%)
|
7.75M
7.75M – 7.75M
-12.2% YoY
|
6.14M
6.14M – 6.14M
-20.7% YoY
|
1.60M
1.60M – 1.60M
-74.0% YoY
|
893.1K
893.1K – 893.1K
-44.1% YoY
|
503.6K
503.6K – 503.6K
-43.6% YoY
|
| EBIT |
-79.13M
est: 490.6K (-16,229.3%)
|
-59.65M
est: 1.60M (-3,820.9%)
|
-41.98M
est: 8.53M (-591.9%)
|
7.50M
7.50M – 7.50M
-12.2% YoY
|
5.94M
5.94M – 5.94M
-20.7% YoY
|
1.55M
1.55M – 1.55M
-74.0% YoY
|
863.8K
863.8K – 863.8K
-44.1% YoY
|
487.1K
487.1K – 487.1K
-43.6% YoY
|
| Net Income |
-76.40M
est: -124.63M (+38.7%)
|
-58.24M
est: -1.32B (+95.6%)
|
-35.04M
est: -573.43M (+93.9%)
|
-252.45M
-252.45M – -252.45M
+56.0% YoY
|
-216.50M
-216.50M – -216.50M
+14.2% YoY
|
-304.27M
-304.27M – -304.27M
-40.5% YoY
|
-242.41M
-242.41M – -242.41M
+20.3% YoY
|
-238.23M
-238.23M – -238.23M
+1.7% YoY
|
| SGA |
27.00M
est: 3.58M (+655.1%)
|
24.78M
est: 11.68M (+112.1%)
|
29.71M
est: 62.19M (-52.2%)
|
54.62M
54.62M – 54.62M
-12.2% YoY
|
43.31M
43.31M – 43.31M
-20.7% YoY
|
11.27M
11.27M – 11.27M
-74.0% YoY
|
6.30M
6.30M – 6.30M
-44.1% YoY
|
3.55M
3.55M – 3.55M
-43.6% YoY
|
| EPS |
-38.92
est: -1.49 (-2,510.4%)
|
-15.26
est: -15.94 (+4.3%)
|
-4.19
est: -6.86 (+38.9%)
|
-3.02
-3.02 – -3.02
+56.0% YoY
|
-2.59
-2.59 – -2.59
+14.2% YoY
|
-3.64
-3.64 – -3.64
-40.5% YoY
|
-2.90
-2.90 – -2.90
+20.3% YoY
|
-2.85
-2.85 – -2.85
+1.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
12.04M
OE per share TTM
-0.57
Owner's Yield
0.87%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
157.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
24
Total invested
22.03M
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 7.35M | 19.90% | 7.35M | — | 7.35M | — | CO | Delaware | 2024-04-05 | ↗ |
| 2 | GKCC, LLC | 7.00M | 15.90% | 7.00M | — | 7.00M | — | OO | Delaware | 2024-09-27 | ↗ |
| 3 | Yekaterina Chudnovsky | 7.00M | 15.90% | 7.00M | — | 7.00M | — | IN | Delaware | 2024-09-27 | ↗ |
| 4 | OCTAGON CAPITAL ADVISORS LP | 2.43M | 8.83% | — | 2.43M | — | 2.43M | IA, PN | Delaware | 2023-01-25 | ↗ |
| 5 | OCTAGON INVESTMENTS MASTER FUND LP | 2.43M | 8.83% | — | 2.43M | — | 2.43M | PN, OO | Delaware | 2023-01-25 | ↗ |
| 6 | TING JIA | 2.43M | 8.83% | — | 2.43M | — | 2.43M | HC, IN | Delaware | 2023-01-25 | ↗ |
| 7 | Atlas Venture Associates XI, L.P. | 2.02M | 7.60% | — | 2.02M | — | 2.02M | PN | Delaware | 2021-11-05 | ↗ |
| 8 | MRL Ventures Fund, LLC | 1.48M | 5.40% | — | 1.48M | — | 1.48M | CO | New Jersey | 2023-04-10 | ↗ |
| 9 | Merck & Co., Inc. | 1.48M | 5.40% | — | 1.48M | — | 1.48M | HC, CO | New Jersey | 2023-04-10 | ↗ |
| 10 | Merck Sharp & Dohme Corp. | 1.48M | 5.40% | — | 1.48M | — | 1.48M | CO | New Jersey | 2023-04-10 | ↗ |
| 11 | Takeda Pharmaceutical Company Limited | 1.48M | 5.37% | — | 1.48M | — | — | CO | — | 2022-01-14 | ↗ |
| 12 | Takeda Ventures, Inc. | 1.48M | 5.37% | — | 1.48M | — | — | CO | — | 2022-01-14 | ↗ |
| 13 | John P. McKearn, Ph.D | 1.44M | 5.40% | — | 1.44M | — | 1.44M | IN | — | 2021-11-05 | ↗ |
| 14 | L.P. | 1.44M | 5.40% | — | 1.44M | — | 1.44M | PN | — | 2021-11-05 | ↗ |
| 15 | LLC | 1.44M | 5.40% | — | 1.44M | — | 1.44M | OO | — | 2021-11-05 | ↗ |
| 16 | Ph.D. | 1.44M | 5.40% | — | 1.44M | — | 1.44M | IN | — | 2021-11-05 | ↗ |
| 17 | Rock Springs Capital LLC | 1.44M | 5.23% | — | 1.44M | — | — | HC, OO | Delaware | 2024-02-14 | ↗ |
| 18 | Rock Springs Capital Management LP | 1.44M | 5.23% | — | 1.44M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 19 | Bain Capital Life Sciences Fund II, L.P. | 1.35M | 5.10% | — | 1.35M | — | 1.35M | PN | Cayman Islands | 2021-11-05 | ↗ |
| 20 | BCLS II Investco, LP | 1.25M | 4.70% | — | 1.25M | — | 1.25M | PN | Cayman Islands | 2021-11-05 | ↗ |
| 21 | Atlas Venture Associates Opportunity I, L.P. | 735.9K | 2.80% | — | 735.9K | — | 735.9K | PN | Delaware | 2021-11-05 | ↗ |
| 22 | Atlas Venture Opportunity Fund I, L.P. | 735.9K | 2.80% | — | 735.9K | — | 735.9K | PN | Delaware | 2021-11-05 | ↗ |
| 23 | BCIP Life Sciences Associates, LP | 164.3K | 0.60% | — | 164.3K | — | 164.3K | PN | Cayman Islands | 2021-11-05 | ↗ |
| 24 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-11-14 | ↗ |
| 25 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 26 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2022-11-14 | ↗ |
| 27 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
24
-13 vs prev Q
New positions
7
Closed positions
20
Increased
8
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EMPERY ASSET MANAGEMENT, LP | 1.18M +1.2M (+100.0%) | 757.38M +757.4M (+100.0%) | 0.82% +0.821 pp | 0.67% +0.668 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 2 | GILEAD SCIENCES, INC. | 9.11M +— (+0.0%) | 5.83M -1.8M (-24.0%) | 6.32% -3.122 pp | 0.30% -0.127 pp | USD0.96 -33.3% | 5 qtrs — |
| 3 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 7.37M +2.8M (+61.4%) | 4.72M +871.5K (+22.6%) | 5.12% +0.381 pp | 0.36% +0.106 pp | USD6.54 -90.2% | 17 qtrs — |
| 4 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 5.92M +5.9M (+100.0%) | 3.79M +3.8M (+100.0%) | 4.10% +4.105 pp | 0.10% +0.102 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 5 | POINT72 ASSET MANAGEMENT, L.P. | 4.00M +4.0M (+100.0%) | 2.56M +2.6M (+100.0%) | 2.78% +2.776 pp | 0.00% +0.003 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 6 | SIO CAPITAL MANAGEMENT, LLC | 2.13M +2.1M (+100.0%) | 1.37M +1.4M (+100.0%) | 1.48% +1.481 pp | 0.22% +0.215 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 7 | STEMPOINT CAPITAL LP | 2.03M +2.0M (+100.0%) | 1.30M +1.3M (+100.0%) | 1.41% +1.409 pp | 0.22% +0.223 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 8 | MERCK & CO., INC. | 1.48M +— (+0.0%) | 949.9K -300.5K (-24.0%) | 1.03% -0.509 pp | 0.34% -0.205 pp | USD0.96 -33.3% | 5 qtrs — |
| 9 | VANGUARD GROUP INC | 1.26M +— (+0.0%) | 803.6K -254.9K (-24.1%) | 0.87% -0.431 pp | 0.00% +0.000 pp | USD6.62 -90.3% | 17 qtrs — |
| 10 | GHISALLO CAPITAL MANAGEMENT LLC | 1.11M +1.1M (+100.0%) | 712.7K +712.7K (+100.0%) | 0.77% +0.773 pp | 0.03% +0.032 pp | USD0.64 +0.0% | 3 qtrs — |
| 11 | MORGAN STANLEY | 839.9K -122.1K (-12.7%) | 537.7K -272.9K (-33.7%) | 0.58% -0.415 pp | 0.00% +0.000 pp | USD0.87 -26.4% | 17 qtrs — |
| 12 | AJU IB INVESTMENT CO., LTD. | 667.7K +— (+0.0%) | 427.5K -168.1K (-28.2%) | 0.46% -0.229 pp | 1.88% +1.359 pp | USD0.96 -33.3% | 5 qtrs — |
| 13 | FMR LLC | 511.8K +— (+0.0%) | 327.7K -103.6K (-24.0%) | 0.36% -0.176 pp | 0.00% +0.000 pp | USD15.93 -96.0% | 17 qtrs — |
| 14 | CITADEL ADVISORS LLC | 436.2K +436.2K (+100.0%) | 279.3K +279.3K (+100.0%) | 0.30% +0.303 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 344.4K +139.7K (+68.3%) | 220.5K +48.0K (+27.8%) | 0.24% +0.027 pp | 0.00% +0.000 pp | USD0.79 -19.0% | 15 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 329.0K +— (+0.0%) | 210.6K -66.6K (-24.0%) | 0.23% -0.113 pp | 0.00% +0.000 pp | USD4.08 -84.3% | 17 qtrs — |
| 17 | STATE STREET CORP | 186.4K +22.5K (+13.7%) | 119.3K -18.8K (-13.6%) | 0.13% -0.041 pp | 0.00% +0.000 pp | USD1.83 -65.0% | 17 qtrs — |
| 18 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 170.0K +170.0K (+100.0%) | 108.8K +108.8K (+100.0%) | 0.12% +0.118 pp | 0.06% +0.063 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 19 | GSA CAPITAL PARTNERS LLP | 148.0K +148.0K (+100.0%) | 95.0K +95.0K (+100.0%) | 0.10% +0.103 pp | 0.01% +0.008 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 20 | STONEPINE CAPITAL MANAGEMENT, LLC | 126.3K +126.3K (+100.0%) | 80.8K +80.8K (+100.0%) | 0.09% +0.088 pp | 0.06% +0.059 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 21 | NORTHERN TRUST CORP | 66.6K +— (+0.0%) | 42.6K -13.5K (-24.0%) | 0.05% -0.023 pp | 0.00% +0.000 pp | USD3.90 -83.6% | 17 qtrs — |
| 22 | TWO SIGMA INVESTMENTS, LP | 62.0K -25.8K (-29.3%) | 39.7K -34.3K (-46.3%) | 0.04% -0.048 pp | 0.00% 0.000 pp | USD0.75 -14.7% | 6 qtrs — |
| 23 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 56.1K +— (+0.0%) | 35.9K -11.4K (-24.0%) | 0.04% -0.019 pp | 0.00% 0.000 pp | USD2.18 -70.6% | 14 qtrs — |
| 24 | JANE STREET GROUP, LLC | 42.1K +42.1K (+100.0%) | 26.9K +26.9K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 25 | HRT FINANCIAL LP | 31.9K +7.2K (+28.9%) | 20.0K +— (+0.0%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD0.80 -20.0% | 2 qtrs — |
| 26 | MARINER, LLC | 25.0K +— (+0.0%) | 16.0K -5.1K (-24.0%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD0.79 -19.0% | 6 qtrs — |
| 27 | LPL FINANCIAL LLC | 21.0K -10.0K (-32.3%) | 13.4K -12.7K (-48.5%) | 0.01% -0.018 pp | 0.00% +0.000 pp | USD0.68 -5.9% | 3 qtrs — |
| 28 | RAYMOND JAMES FINANCIAL INC | 18.8K +— (+0.0%) | 12.0K -3.8K (-24.0%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD0.95 -32.6% | 5 qtrs — |
| 29 | XTX TOPCO LTD | 17.3K -58.7K (-77.2%) | 11.1K -53.0K (-82.7%) | 0.01% -0.067 pp | 0.00% -0.003 pp | USD0.77 -16.9% | 7 qtrs — |
| 30 | DUNHILL FINANCIAL, LLC | 10.3K +— (+0.0%) | 6.6K -2.1K (-24.0%) | 0.01% -0.004 pp | 0.00% -0.001 pp | USD0.72 -11.1% | 9 qtrs — |
| 31 | PINNACLE FINANCIAL GROUP, LLC / IL | 10.0K +— (+0.0%) | 6.4K -2.0K (-24.0%) | 0.01% -0.003 pp | 0.00% -0.001 pp | USD0.92 -30.4% | 7 qtrs — |
| 32 | INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV | 10.0K +— (+0.0%) | 6.4K -2.0K (-24.0%) | 0.01% -0.003 pp | 0.00% -0.001 pp | USD0.72 -11.1% | 4 qtrs — |
| 33 | BLACKROCK, INC. | 2.0K +— (+0.0%) | 1.3K -413.0 (-24.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD0.79 -19.0% | 6 qtrs — |
| 34 | KEY FINANCIAL INC | 830.00 +— (+0.0%) | 531.00 -160.0 (-23.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.17 -79.8% | 12 qtrs — |
| 35 | PRIVATE WEALTH MANAGEMENT GROUP, LLC | 310.00 +— (+0.0%) | 199.00 -63.0 (-24.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.79 -19.0% | 6 qtrs — |
| 36 | BANK OF AMERICA CORP /DE/ | 261.00 +15.0 (+6.1%) | 167.00 -40.0 (-19.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.85 -24.7% | 13 qtrs — |
| 37 | UBS GROUP AG | 203.00 -13.4K (-98.5%) | 130.00 -11.4K (-98.9%) | 0.00% -0.014 pp | 0.00% +0.000 pp | USD0.86 -25.6% | 17 qtrs — |
| 38 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | — -3.3K (-100.0%) | — -2.8K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 39 | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | — -249.6K (-100.0%) | — -210.4K (-100.0%) | 0.00% -0.259 pp | 0.00% -0.032 pp | USD— | 5 qtrs SOLD |
| 40 | TWO SIGMA ADVISERS, LP | — -29.7K (-100.0%) | — -25.0K (-100.0%) | 0.00% -0.031 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 41 | SQUAREPOINT OPS LLC | — -328.8K (-100.0%) | — -277.1K (-100.0%) | 0.00% -0.341 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 42 | TWO SIGMA SECURITIES, LLC | — -32.1K (-100.0%) | — -27.1K (-100.0%) | 0.00% -0.033 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 43 | BALYASNY ASSET MANAGEMENT L.P. | — -198.9K (-100.0%) | — -167.6K (-100.0%) | 0.00% -0.206 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
| 44 | APTUS CAPITAL ADVISORS, LLC | — -25.0K (-100.0%) | — -21.1K (-100.0%) | 0.00% -0.026 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 45 | SEVENBRIDGE FINANCIAL GROUP, LLC | — -25.0K (-100.0%) | — -19.3K (-100.0%) | 0.00% -0.026 pp | 0.00% -0.003 pp | USD— | 8 qtrs SOLD |
| 46 | CITIGROUP INC | — -258.0 (-100.0%) | — -217.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 75.4K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 294.4K | 0.05% |
| 3 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 10.3K | 0.14% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.0K | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.1K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 223.42 | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 517.0K | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.1K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 616.62 | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 249.16 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
10.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+10,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Blanchard Cheryl R | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 8.40 | 84.0K | 10,000 | D | ↗ |
| 2026-03-26 | Shannon James Samuel | Director | P-Purchase | A | Common Stock | 5,000 | 8.79 | 44.0K | 10,000 | D | ↗ |
| 2026-02-13 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Prefunded Warrants (right to buy) | 3,739,000 | 0.00 | 373.90 | 40,384,266 | D | ↗ |
| 2026-01-02 | Frankenfield Christopher James | Officer | S-Sale | D | Common Stock | 7,030 | 0.64 | 4.5K | 24,766 | D | ↗ |
| 2026-01-02 | Brennan Kevin M. | Officer | S-Sale | D | Common Stock | 1,826 | 0.64 | 1.2K | 6,371 | D | ↗ |
| 2026-01-01 | Russo Rene | Director / Officer | M-Exempt | D | Restricted Stock Units | 44,250 | 0.00 | — | 88,500 | D | ↗ |
| 2026-01-01 | Luptakova Katarina | Officer | M-Exempt | D | Restricted Stock Units | 16,625 | 0.00 | — | 33,250 | D | ↗ |
| 2026-01-01 | Frankenfield Christopher James | Officer | M-Exempt | A | Common Stock | 19,375 | 0.00 | — | 31,796 | D | ↗ |
| 2026-01-01 | Brennan Kevin M. | Officer | M-Exempt | D | Restricted Stock Units | 5,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-12-31 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,500,258 | 0.84 | 1.26M | 1,500,258 | D | ↗ |
| 2025-12-31 | Luptakova Katarina | Officer | A-Award | A | Stock Option (right to buy) | 451,885 | 0.84 | 380.0K | 451,885 | D | ↗ |
| 2025-12-31 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (right to buy) | 668,789 | 0.84 | 562.5K | 668,789 | D | ↗ |
| 2025-12-31 | Brennan Kevin M. | Officer | A-Award | A | Stock Option (right to buy) | 95,221 | 0.84 | 80.1K | 95,221 | D | ↗ |
| 2025-11-26 | GILEAD SCIENCES, INC. | 10% Owner | X-InTheMoney | A | Prefunded Warrants (right to buy) | 13,335,000 | 0.00 | 1.3K | 36,645,266 | D | ↗ |
| 2025-11-21 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 473,334 | 1.50 | 710.0K | 473,334 | D | ↗ |
| 2025-11-21 | Luptakova Katarina | Officer | D-Return | D | Stock Option (right to buy) | 35,000 | 2.69 | 94.2K | 0 | D | ↗ |
| 2025-11-21 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (right to buy) | 925,000 | 0.84 | 777.9K | 925,000 | D | ↗ |
| 2025-11-21 | Brennan Kevin M. | Officer | D-Return | D | Stock Option (right to buy) | 25,000 | 2.79 | 69.6K | 0 | D | ↗ |
| 2025-06-17 | Shannon James Samuel | Director | P-Purchase | A | Common Stock | 25,000 | 0.69 | 17.2K | 70,000 | D | ↗ |
| 2025-06-16 | Shannon James Samuel | Director | P-Purchase | A | Common Stock | 45,000 | 0.69 | 30.9K | 45,000 | D | ↗ |
| 2025-06-16 | Russo Rene | Director / Officer | P-Purchase | A | Common Stock | 36,289 | 0.68 | 24.7K | 281,172 | D | ↗ |
| 2025-06-11 | Xu Yuan | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | Shannon James Samuel | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | Rossi Christina | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | ROSS ROBERT W. | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | Curran Daniel J. | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | Clancy Paul J | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | Brennan Aoife | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-11 | Bonstein Sara | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 0.69 | 21.5K | 31,000 | D | ↗ |
| 2025-06-10 | Bello Akintunde Olatokumbo | Director | A-Award | A | Stock Option (right to buy) | 62,000 | 0.70 | 43.4K | 62,000 | D | ↗ |
| 2025-06-05 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Prefunded Warrants (right to buy) | 13,335,000 | 0.00 | 1.3K | 23,310,266 | D | ↗ |
| 2025-04-15 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 190,000 | 0.71 | 135.3K | 190,000 | D | ↗ |
| 2025-04-15 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 0.71 | 53.4K | 75,000 | D | ↗ |
| 2025-01-02 | Frankenfield Christopher James | Officer | S-Sale | D | Common stock | 6,954 | 0.98 | 6.8K | 12,421 | D | ↗ |
| 2025-01-02 | Brennan Kevin M. | Officer | S-Sale | D | Common stock | 1,803 | 0.98 | 1.8K | 3,197 | D | ↗ |
| 2025-01-01 | Russo Rene | Director / Officer | M-Exempt | D | Restricted Stock Units | 44,250 | 0.00 | — | 132,750 | D | ↗ |
| 2025-01-01 | Luptakova Katarina | Officer | M-Exempt | D | Restricted Stock Units | 16,625 | 0.00 | — | 49,875 | D | ↗ |
| 2025-01-01 | Frankenfield Christopher James | Officer | M-Exempt | A | Common Stock | 19,375 | 0.00 | — | 19,375 | D | ↗ |
| 2025-01-01 | Brennan Kevin M. | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 5,000 | D | ↗ |
| 2024-12-18 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Prefunded Warrants (right to buy) | 6,092,816 | 0.00 | 609.28 | 9,975,266 | D | ↗ |
| 2024-10-01 | Brennan Kevin M. | Officer | A-Award | A | Stock Option (right to buy) | 26,000 | 0.75 | 19.5K | 26,000 | D | ↗ |
| 2024-08-03 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (right to buy) | 52,000 | 0.90 | 46.5K | 52,000 | — | ↗ |
| 2024-06-14 | Xu Yuan | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2024-06-14 | Rossi Christina | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2024-06-14 | ROSS ROBERT W. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2024-06-14 | Curran Daniel J. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2024-06-14 | Clancy Paul J | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2024-06-14 | Bonstein Sara | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2024-06-13 | Shannon James Samuel | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.05 | 52.5K | 50,000 | — | ↗ |
| 2024-06-13 | Brennan Aoife | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.05 | 52.5K | 50,000 | — | ↗ |
| 2024-06-07 | Chudnovsky Yekaterina | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 7,000,000 | I | ↗ |
| 2024-05-01 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 474,000 | 1.08 | 511.9K | 474,000 | — | ↗ |
| 2024-05-01 | Luptakova Katarina | Officer | A-Award | A | Stock Option (right to buy) | 59,333 | 1.08 | 64.1K | 59,333 | — | ↗ |
| 2024-05-01 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (right to buy) | 208,000 | 1.08 | 224.6K | 208,000 | — | ↗ |
| 2024-05-01 | Brennan Kevin M. | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 1.08 | 21.6K | 20,000 | — | ↗ |
| 2024-04-02 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 485,250 | 0.76 | 368.8K | 7,345,473 | — | ↗ |
| 2024-03-27 | GILEAD SCIENCES, INC. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,860,223 | — | ↗ |
| 2024-02-08 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 733 | 0.64 | 469.12 | 2,019,563 | — | ↗ |
| 2024-01-12 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 560 | 0.83 | 464.80 | 734,813 | — | ↗ |
| 2024-01-11 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 569 | 0.87 | 495.03 | 735,373 | — | ↗ |
| 2024-01-01 | Russo Rene | Director / Officer | A-Award | A | Restricted Stock Units | 177,000 | 0.00 | — | 177,000 | — | ↗ |
| 2024-01-01 | Luptakova Katarina | Officer | A-Award | A | Restricted Stock Units | 66,500 | 0.00 | — | 66,500 | — | ↗ |
| 2024-01-01 | Frankenfield Christopher James | Officer | A-Award | A | Restricted Stock Units | 77,500 | 0.00 | — | 77,500 | — | ↗ |
| 2024-01-01 | Brennan Kevin M. | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-09-05 | Luptakova Katarina | Officer | A-Award | A | Stock Option (Right to Buy) | 106,000 | 2.79 | 295.7K | 106,000 | — | ↗ |
| 2023-08-16 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 700,000 | 2.79 | 1.95M | 700,000 | — | ↗ |
| 2023-08-16 | Huber Martin H. Jr. | Officer | A-Award | A | Stock Option (right to buy) | 136,500 | 2.79 | 380.2K | 136,500 | — | ↗ |
| 2023-08-16 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 2.79 | 835.5K | 300,000 | — | ↗ |
| 2023-08-16 | Brennan Kevin M. | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 2.79 | 69.6K | 25,000 | — | ↗ |
| 2023-08-03 | Frankenfield Christopher James | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.75 | 412.5K | 150,000 | — | ↗ |
| 2023-06-12 | Xu Yuan | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.80 | 37.0K | 13,200 | — | ↗ |
| 2023-06-12 | Rossi Christina | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.80 | 37.0K | 13,200 | — | ↗ |
| 2023-06-12 | ROSS ROBERT W. | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.80 | 37.0K | 13,200 | — | ↗ |
| 2023-06-12 | Heyman Tomas J. | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.80 | 37.0K | 13,200 | — | ↗ |
| 2023-06-12 | Clancy Paul J | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.80 | 37.0K | 13,200 | — | ↗ |
| 2023-06-12 | Bonstein Sara | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.80 | 37.0K | 13,200 | — | ↗ |
| 2023-04-01 | Brennan Kevin M. | Officer | A-Award | A | Stock Option (right to buy) | 55,000 | 3.17 | 174.4K | 55,000 | — | ↗ |
| 2023-03-30 | Brennan Kevin M. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-01 | Russo Rene | Director | A-Award | A | Stock Option (right to buy) | 350,000 | 0.00 | — | 350,000 | — | ↗ |
| 2023-01-01 | Huber Martin H. Jr. | Director | A-Award | A | Stock Option (right to buy) | 136,500 | 0.00 | — | 136,500 | — | ↗ |
| 2023-01-01 | English Edward C | Director / Officer | A-Award | A | Stock Option (right to buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-11-09 | English Edward C | Director / Officer | — | D | Stock Option (right to buy) | 20,200 | 12.66 | 255.7K | — | — | ↗ |
| 2022-09-15 | Heyman Tomas J. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-15 | Xu Yuan | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 0.00 | — | 13,200 | — | ↗ |
| 2022-06-15 | Rossi Christina | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.28 | 30.1K | 13,200 | — | ↗ |
| 2022-06-15 | Ross Michael Jay | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.28 | 30.1K | 13,200 | — | ↗ |
| 2022-06-15 | ROSS ROBERT W. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-15 | Huber Martin H. Jr. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | Clancy Paul J | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 2.28 | 30.1K | 13,200 | — | ↗ |
| 2022-06-15 | Bonstein Sara | Director | A-Award | A | Stock Option (right to buy) | 13,200 | 0.00 | — | 13,200 | — | ↗ |
| 2022-02-22 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 12.66 | 1.90M | 150,000 | — | ↗ |
| 2022-02-22 | Huber Martin H. Jr. | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 12.66 | 822.9K | 65,000 | — | ↗ |
| 2022-02-22 | Giovine Salvatore | Officer | A-Award | A | Stock Option (right to buy) | 49,500 | 12.66 | 626.7K | 49,500 | — | ↗ |
| 2022-01-04 | Xu Yuan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-22 | Russo Rene | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 13.83 | 1.38M | 100,000 | — | ↗ |
| 2021-12-10 | Bain Capital Life Sciences Investors, LLC | 10% Owner | P-Purchase | A | Common Stock | 3,188 | 10.24 | 32.6K | 2,805,413 | — | ↗ |
| 2021-12-09 | Bain Capital Life Sciences Investors, LLC | 10% Owner | P-Purchase | A | Common Stock | 4,011 | 9.84 | 39.5K | 2,780,413 | — | ↗ |
| 2021-12-08 | Bain Capital Life Sciences Investors, LLC | 10% Owner | P-Purchase | A | Common Stock | 13,458 | 9.62 | 129.5K | 2,776,402 | — | ↗ |
| 2021-10-26 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | C-Conversion | D | Series C Preferred Stock | 226,941 | 0.00 | — | 0 | — | ↗ |
| 2021-10-26 | SV7 Impact Medicine Fund LP | Director | C-Conversion | A | Common Stock | 998,544 | 0.00 | — | 998,544 | — | ↗ |
| 2021-10-26 | Rock Springs Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 500,000 | 16.00 | 8.00M | 1,256,472 | — | ↗ |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | 10% Owner | C-Conversion | A | Common Stock | 359,324 | 0.00 | — | 1,191,444 | — | ↗ |
| 2021-10-26 | Merck KGaA | 10% Owner | C-Conversion | D | Series C Preferred Srock | 2,515,271 | 0.00 | — | 0 | — | ↗ |
| 2021-10-26 | Flynn James E | 10% Owner | P-Purchase | A | Common Stock | 387,500 | 16.00 | 6.20M | 1,143,972 | — | ↗ |
| 2021-10-26 | FMR LLC | — | C-Conversion | A | Common Stock | 686,499 | 0.00 | — | 1,502,287 | — | ↗ |
| 2021-10-26 | FIL Ltd | — | C-Conversion | A | Common Stock | 218,705 | 0.00 | — | 218,705 | — | ↗ |
| 2021-10-26 | Clancy Paul J | Director | A-Award | A | Stock Option (right to buy) | 65,528 | 5.89 | 386.0K | 65,528 | — | ↗ |
| 2021-10-26 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,762,944 | — | ↗ |
| 2021-10-26 | BAY CITY CAPITAL LLC | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 16.00 | 5.00M | 1,129,490 | — | ↗ |
| 2021-10-26 | Atlas Venture Fund XI, L.P. | 10% Owner | C-Conversion | A | Common Stock | 624,089 | 0.00 | 624.09 | 2,023,402 | — | ↗ |
| 2021-10-26 | Alexandria Venture Investments, LLC | 10% Owner | C-Conversion | A | Common stock | 166,423 | 0.00 | — | 166,423 | — | ↗ |
| 2021-10-21 | Williams John Charles | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 100,080 | — | ↗ |
| 2021-10-21 | TOMLINSON SIMON M | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 131,117 | — | ↗ |
| 2021-10-21 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | — | I | Series C Preferred Stock | 226,941 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | SV7 Impact Medicine Fund LP | 10% Owner | — | I | Series B Convertible Preferred Stock | 998,544 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Russo Rene | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 68,872 | 5.51 | 379.5K | 0 | — | ↗ |
| 2021-10-21 | Rossi Christina | Director | — | D | Stock Option (right to buy) | 53,213 | 10.07 | 535.9K | 0 | — | ↗ |
| 2021-10-21 | Ross Michael Jay | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Rock Springs Capital Management LP | 10% Owner | — | I | Series C Preferred Stock | 151,294 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | RiverVest Venture Fund IV, L.P. | 10% Owner | — | I | Series C Preferred Stock | 359,324 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Merck KGaA | 10% Owner | — | I | Series C Preferred Stock | 264,765 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | LYNCH DANIEL | Director / 10% Owner | — | D | Stock Option (right to buy) | 134,797 | 5.51 | 742.7K | 0 | — | ↗ |
| 2021-10-21 | Huber Martin H. Jr. | Officer | — | D | Stock Option (right to buy) | 77,786 | 11.69 | 909.3K | 0 | — | ↗ |
| 2021-10-21 | HUMPHREY RACHEL | Director | — | D | Common Stock | 0 | 0.00 | — | 9,444 | — | ↗ |
| 2021-10-21 | Giovine Salvatore | Officer | — | D | Stock Option (right to buy) | 233,596 | 6.65 | 1.55M | 0 | — | ↗ |
| 2021-10-21 | Flynn James E | 10% Owner | — | I | Series C Preferred Stock | 756,472 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | FMR LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 26,315 | — | ↗ |
| 2021-10-21 | Estate of Ulrich Rodeck | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 100,080 | — | ↗ |
| 2021-10-21 | Curran Daniel J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Clancy Paul J | Director | — | D | Stock Option (right to buy) | 23,364 | 5.51 | 128.7K | 0 | — | ↗ |
| 2021-10-21 | CLACKSON TIMOTHY P | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 70,888 | — | ↗ |
| 2021-10-21 | Bonstein Sara | Director | — | D | Stock Option (right to buy) | 53,213 | 11.69 | 622.1K | 0 | — | ↗ |
| 2021-10-21 | BAY CITY CAPITAL LLC | 10% Owner | — | I | Series C Preferred Stock | 151,294 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Atlas Venture Fund XI, L.P. | 10% Owner | — | I | Series A1 Preferred Stock | 1,372,998 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Alexandria Venture Investments, LLC | 10% Owner | — | D | Series B convertible preferred stock | 166,423 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-656.0K
Shares Outstanding
5.98M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | René Russo, Pharm.D. President and Chief Executive Officer | 643.7K | 128.7K | — | 5.29M | 371.7K | 14.0K | 6.45M | 82.05% | ↗ |
| 2 | 2025 | Christopher Frankenfield Chief Financial and Operating Officer | 533.1K | 106.6K | — | 2.29M | 287.9K | 14.0K | 3.23M | 70.84% | ↗ |
| 3 | 2025 | Katarina Luptakova, M.D. Chief Medical Officer | 481.3K | — | — | 1.51M | 196.4K | 14.0K | 2.20M | 68.52% | ↗ |
| 4 | 2024 | René Russo, Pharm.D. President and Chief Executive Officer | 613.9K | — | 97.4K | 391.8K | 337.7K | 14.0K | 1.45M | 33.62% | ↗ |
| 5 | 2024 | Christopher Frankenfield Chief Financial and Operating Officer | 506.1K | — | 42.6K | 207.5K | 265.7K | 14.0K | 1.04M | 24.14% | ↗ |
| 6 | 2024 | Katarina Luptakova, M.D. Chief Medical Officer | 465.0K | — | 36.6K | 49.0K | 182.3K | 14.0K | 746.9K | 11.46% | ↗ |
| 7 | 2023 | René Russo, Pharm.D. President and Chief Executive Officer | 598.0K | — | — | 2.12M | 263.1K | 14.0K | 3.00M | 70.83% | ↗ |
| 8 | 2023 | Christopher Frankenfield Chief Financial and Operating Officer | 481.1K | — | — | 1.16M | 210.0K | 13.7K | 1.86M | 62.12% | ↗ |
| 9 | 2023 | Christopher Frankenfield Chief Operating Officer | 481.1K | — | — | 1.16M | 210.0K | 13.7K | 1.86M | 62.12% | ↗ |
| 10 | 2023 | Martin Huber, M.D. Former President and Head of R&D | 358.7K | — | — | 655.4K | — | 15.7K | 1.03M | 63.64% | ↗ |
| 11 | 2023 | Katarina Luptakova, M.D. Chief Medical Officer | 421.7K | — | — | 340.3K | 156.2K | 14.0K | 932.2K | 36.50% | ↗ |
| 12 | 2022 | René Russo, Pharm.D. Chief Executive Officer | 575.0K | — | — | 1.32M | 306.8K | 6.7K | 2.21M | 59.84% | ↗ |
| 13 | 2022 | René Russo, Pharm.D. President and Chief Executive Officer | 575.0K | — | — | 1.32M | 306.8K | 6.7K | 2.21M | 59.84% | ↗ |
| 14 | 2022 | Martin Huber, M.D. Former President and Head of R&D | 488.6K | — | — | 607.5K | 242.5K | 8.9K | 1.35M | 45.08% | ↗ |
| 15 | 2022 | Martin Huber, M.D. President and Head of R&D | 488.6K | — | — | 607.5K | 242.5K | 8.9K | 1.35M | 45.08% | ↗ |
| 16 | 2022 | Salvatore Giovine Former Chief Financial Officer | 256.2K | — | — | 436.8K | — | 252.00 | 693.2K | 63.01% | ↗ |
| 17 | 2021 | René Russo, Pharm.D. President and Chief Executive Officer | 485.0K | — | — | 4.59M | 379.5K | 9.3K | 5.46M | 84.01% | ↗ |
| 18 | 2021 | René Russo, Pharm.D. Chief Executive Officer | 485.0K | — | — | 4.59M | 379.5K | 9.3K | 5.46M | 84.01% | ↗ |
| 19 | 2021 | Martin Huber, M.D. President of R&D and Chief Medical Officer | 458.9K | — | — | 2.72M | 269.3K | 11.3K | 3.46M | 78.63% | ↗ |
| 20 | 2021 | Martin Huber, M.D. President and Head of R&D | 458.9K | — | — | 2.72M | 269.3K | 11.3K | 3.46M | 78.63% | ↗ |
| 21 | 2021 | Salvatore Giovine Chief Financial Officer | 291.6K | 50.0K | — | 1.39M | 193.6K | 299.00 | 1.92M | 72.17% | ↗ |
| 22 | 2021 | Salvatore Giovine Former Chief Financial Officer | 291.6K | 50.0K | — | 1.39M | 193.6K | 299.00 | 1.92M | 72.17% | ↗ |
| 23 | 2020 | René Russo, Pharm.D. President and Chief Executive Officer | 450.0K | — | 1.02M | 854.5K | 182.3K | 633.00 | 2.51M | 74.77% | ↗ |
| 24 | 2020 | Martin Huber, M.D. President of R&D and Chief Medical Officer | 301.5K | — | — | 501.1K | 159.1K | 1.9K | 963.6K | 52.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rene Russo BCPS | President, Chief Executive Officer & Director | 1M | — |
| Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer | 941.6K | male |
| Katarina Luptakova | Chief Medical Officer | 691.7K | — |
| Ruth du Moulin | Senior Vice President of Medical Affairs | — | female |
| Scott Coleman | Chief Development Officer | — | — |
| Caroline Hensley | Chief Legal Officer | — | female |
| Uli Bialucha | Chief Scientific Officer | — | — |
| Kevin Brennan | Senior Vice President of Finance & Accounting | — | male |
| Nathan McBride | Chief Information Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XLO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
